Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: A single-institution experience

Jung Yeon Lee, Haerim Chung, Hyunsoo Cho, Ji Eun Jang, Yundeok Kim, Soo Jeong Kim, Jin Seok Kim, Shin Young Hyun, Yoo Hong Min, June Won Cheong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Isolated myeloid sarcoma (MS) is a rare extramedullary tumor mass composed of malignant myeloid precursor cells without any evidence of leukemia in the peripheral blood and bone marrow. We describe the clinical characteristics and outcomes of patients diagnosed with isolated MS at our institution. Methods We retrospectively reviewed 9 of 497 acute myeloid leukemia (AML) patients (1.8%) with isolated MS. Isolated MS patients were divided into 2 groups according to the first-line treatment strategy: systemic treatment only (S) or local treatment with or without systemic treatment (LS). Results The most common site of MS occurrence was the head and neck area (N=4, 44.4%), followed by the anterior mediastinum (N=2, 22.2%) and the gastrointestinal tract (N=2, 22.2%). The tumors of 4 patients (44.4%) eventually evolved to AML, in a median time of 13.4 months (range, 2.4-20.1 mo). The number of patients achieving complete remission after first-line treatment was higher in the LS group (N=5, 83.3%) than in the S group (N=1, 33.3%) (P =0.226). All patients in the LS group survived, but those in the S group died (P=0.012). Conclusion Accurate and rapid diagnosis using various modalities and the early initiation of intensive combined treatment may be the optimal strategies to reduce the risk of isolated MS subsequently evolving to AML. To fully understand the characteristics of isolated MS, a larger number of patients from a multinational study is necessary.

Original languageEnglish
Pages (from-to)184-192
Number of pages9
JournalBlood Research
Volume52
Issue number3
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Myeloid Sarcoma
Bone Marrow
Acute Myeloid Leukemia
Therapeutics
Mediastinum
Myeloid Cells
Gastrointestinal Tract
Neoplasms
Leukemia
Neck
Head

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Lee, Jung Yeon ; Chung, Haerim ; Cho, Hyunsoo ; Jang, Ji Eun ; Kim, Yundeok ; Kim, Soo Jeong ; Kim, Jin Seok ; Hyun, Shin Young ; Min, Yoo Hong ; Cheong, June Won. / Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement : A single-institution experience. In: Blood Research. 2017 ; Vol. 52, No. 3. pp. 184-192.
@article{1804c31e2a50423a812f110e0b49be04,
title = "Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement: A single-institution experience",
abstract = "Background Isolated myeloid sarcoma (MS) is a rare extramedullary tumor mass composed of malignant myeloid precursor cells without any evidence of leukemia in the peripheral blood and bone marrow. We describe the clinical characteristics and outcomes of patients diagnosed with isolated MS at our institution. Methods We retrospectively reviewed 9 of 497 acute myeloid leukemia (AML) patients (1.8{\%}) with isolated MS. Isolated MS patients were divided into 2 groups according to the first-line treatment strategy: systemic treatment only (S) or local treatment with or without systemic treatment (LS). Results The most common site of MS occurrence was the head and neck area (N=4, 44.4{\%}), followed by the anterior mediastinum (N=2, 22.2{\%}) and the gastrointestinal tract (N=2, 22.2{\%}). The tumors of 4 patients (44.4{\%}) eventually evolved to AML, in a median time of 13.4 months (range, 2.4-20.1 mo). The number of patients achieving complete remission after first-line treatment was higher in the LS group (N=5, 83.3{\%}) than in the S group (N=1, 33.3{\%}) (P =0.226). All patients in the LS group survived, but those in the S group died (P=0.012). Conclusion Accurate and rapid diagnosis using various modalities and the early initiation of intensive combined treatment may be the optimal strategies to reduce the risk of isolated MS subsequently evolving to AML. To fully understand the characteristics of isolated MS, a larger number of patients from a multinational study is necessary.",
author = "Lee, {Jung Yeon} and Haerim Chung and Hyunsoo Cho and Jang, {Ji Eun} and Yundeok Kim and Kim, {Soo Jeong} and Kim, {Jin Seok} and Hyun, {Shin Young} and Min, {Yoo Hong} and Cheong, {June Won}",
year = "2017",
month = "1",
day = "1",
doi = "10.5045/br.2017.52.3.184",
language = "English",
volume = "52",
pages = "184--192",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "3",

}

Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement : A single-institution experience. / Lee, Jung Yeon; Chung, Haerim; Cho, Hyunsoo; Jang, Ji Eun; Kim, Yundeok; Kim, Soo Jeong; Kim, Jin Seok; Hyun, Shin Young; Min, Yoo Hong; Cheong, June Won.

In: Blood Research, Vol. 52, No. 3, 01.01.2017, p. 184-192.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical characteristics and treatment outcomes of isolated myeloid sarcoma without bone marrow involvement

T2 - A single-institution experience

AU - Lee, Jung Yeon

AU - Chung, Haerim

AU - Cho, Hyunsoo

AU - Jang, Ji Eun

AU - Kim, Yundeok

AU - Kim, Soo Jeong

AU - Kim, Jin Seok

AU - Hyun, Shin Young

AU - Min, Yoo Hong

AU - Cheong, June Won

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background Isolated myeloid sarcoma (MS) is a rare extramedullary tumor mass composed of malignant myeloid precursor cells without any evidence of leukemia in the peripheral blood and bone marrow. We describe the clinical characteristics and outcomes of patients diagnosed with isolated MS at our institution. Methods We retrospectively reviewed 9 of 497 acute myeloid leukemia (AML) patients (1.8%) with isolated MS. Isolated MS patients were divided into 2 groups according to the first-line treatment strategy: systemic treatment only (S) or local treatment with or without systemic treatment (LS). Results The most common site of MS occurrence was the head and neck area (N=4, 44.4%), followed by the anterior mediastinum (N=2, 22.2%) and the gastrointestinal tract (N=2, 22.2%). The tumors of 4 patients (44.4%) eventually evolved to AML, in a median time of 13.4 months (range, 2.4-20.1 mo). The number of patients achieving complete remission after first-line treatment was higher in the LS group (N=5, 83.3%) than in the S group (N=1, 33.3%) (P =0.226). All patients in the LS group survived, but those in the S group died (P=0.012). Conclusion Accurate and rapid diagnosis using various modalities and the early initiation of intensive combined treatment may be the optimal strategies to reduce the risk of isolated MS subsequently evolving to AML. To fully understand the characteristics of isolated MS, a larger number of patients from a multinational study is necessary.

AB - Background Isolated myeloid sarcoma (MS) is a rare extramedullary tumor mass composed of malignant myeloid precursor cells without any evidence of leukemia in the peripheral blood and bone marrow. We describe the clinical characteristics and outcomes of patients diagnosed with isolated MS at our institution. Methods We retrospectively reviewed 9 of 497 acute myeloid leukemia (AML) patients (1.8%) with isolated MS. Isolated MS patients were divided into 2 groups according to the first-line treatment strategy: systemic treatment only (S) or local treatment with or without systemic treatment (LS). Results The most common site of MS occurrence was the head and neck area (N=4, 44.4%), followed by the anterior mediastinum (N=2, 22.2%) and the gastrointestinal tract (N=2, 22.2%). The tumors of 4 patients (44.4%) eventually evolved to AML, in a median time of 13.4 months (range, 2.4-20.1 mo). The number of patients achieving complete remission after first-line treatment was higher in the LS group (N=5, 83.3%) than in the S group (N=1, 33.3%) (P =0.226). All patients in the LS group survived, but those in the S group died (P=0.012). Conclusion Accurate and rapid diagnosis using various modalities and the early initiation of intensive combined treatment may be the optimal strategies to reduce the risk of isolated MS subsequently evolving to AML. To fully understand the characteristics of isolated MS, a larger number of patients from a multinational study is necessary.

UR - http://www.scopus.com/inward/record.url?scp=85029865855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029865855&partnerID=8YFLogxK

U2 - 10.5045/br.2017.52.3.184

DO - 10.5045/br.2017.52.3.184

M3 - Article

AN - SCOPUS:85029865855

VL - 52

SP - 184

EP - 192

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 3

ER -